Successful Application of Edoxaban in the Treatment of Venous Thromboembolism Recurrence in a Patient with Non-small Cell Lung Cancer after Tumor Shrinkage.

Abstract

This report describes the case of a 66-year-old man with non-small cell lung cancer and venous thromboembolism (VTE). Unfractionated heparin (UFH) was initially used to control VTE before chemotherapy. However, switching UFH to warfarin or edoxaban, a novel oral anticoagulant (NOAC), failed. Chemotherapy was then administered to control the tumor which was thought to have been the main cause of VTE, which had been treated by UFH. After tumor shrinkage was achieved by chemotherapy, we were able to successfully switch from UFH to edoxaban. Controlling the tumor size and activity enabled the use of edoxaban as maintenance therapy for VTE.

• Authors: Tetsuaki Shoji, Hidenori Mizugaki, Yasuyuki Ikezawa, Megumi Furuta, Yuta Takashima, Hajime Kikuchi, Houman Goudarzi, Hajime Asahina, Junko Kikuchi, Eiki Kikuchi, Jun Sakakibara-Konishi, Naofumi Shinagawa, Ichizo Tsujino, Masaharu Nishimura
• Journal: Internal medicine (Tokyo, Japan) (Intern Med) Vol. 57 Issue 12 Pg. 1769-1772 (Jun 15 2018) ISSN: 1349-7235 [Electronic] Japan
• PMID: 29434159 (Publication Type: Case Reports, Journal Article)

Chemical References

• Anticoagulants
• Pyridines
• Thiazoles
• Warfarin
• Heparin
• edoxaban

Topics

• Aged
• Anticoagulants (therapeutic use)
• Carcinoma, Non-Small-Cell Lung (complications, pathology)
• Heparin (therapeutic use)
• Humans
• Lung Neoplasms (complications, pathology)
• Male
• Pyridines (therapeutic use)
• Thiazoles (therapeutic use)
• Tumor Burden
• Venous Thromboembolism (complications, drug therapy)
• Warfarin (therapeutic use)